Next-Generation TILs

We are developing a next-generation technology based on genetically engineered and presorted tumor infiltrating lymphocytes (TILs), which offer a number of important benefits:

  • Greater potency and persistence
  • Lower cost of goods, shorter manufacturing process
  • Cytokine expression enhances modulation of immune-suppressing proteins PD-1 and CTLA-4
  • Lower cell numbers required
  • Stronger intellectual property protection